reported that 272 of the 824 patients (33 percent) with mild to moderate carpal tunnel syndrome who underwent a local corticosteroid injection required surgery at 5-year follow-up. 13 This indicates that there is a subgroup of patients who will achieve lasting symptom improvement from an injection.
It would be important to identify the likelihood of long-term benefit from a local steroid injection. For those unlikely to have long-term benefit, surgery would be a more appropriate option, as it would hasten the resolution of symptoms, and avoid the discomfort or potential complications of an injection. For those likely to have long-term benefit, injection therapy would prevent unnecessary surgery and reduce health care costs. Previous studies have investigated predictors for subsequent treatment of carpal tunnel syndrome after initial injection. A diagnosis of diabetes mellitus, higher preinjection score on the Boston Carpal Tunnel Questionnaire, longer duration of symptoms, and a more severe electrodiagnostic study result have all been suggested as risk factors for poor clinical outcome following a local corticosteroid injection. [11] [12] [13] [14] [15] However, these results are not consistent across different studies. The purpose of this study was to determine the long-term rate of reintervention (additional injection or surgery) after a single corticosteroid injection in the management of carpal tunnel syndrome and to identify prognostic indicators for subsequent treatment in a population-based cohort.
PATIENTS AND METHODS

Data Collection
This retrospective study is based on data from residents of Olmsted County, Minnesota, treated with a corticosteroid injection for carpal tunnel syndrome between 2001 and 2010. Patients were identified using the resources of the Rochester Epidemiology Project medical records linkage system. 16 The Rochester Epidemiology Project organizes demographic data, diagnostic codes, and surgical procedure codes in electronic indexes that can be searched. Patients' residency status is also checked. Multiple medical records for the same individual are linked within and across institutions to create a comprehensive record, regardless of where a county resident is seen. 17 Participating institutions and providers include not only those within Olmsted County but also those in the surrounding region. Studies have shown that the database includes nearly all care provided to nearly all (i.e., >90 percent) Olmsted County residents. Our selection was based on a Current Procedural Terminology code for diagnosis of carpal tunnel syndrome (International Classification of Diseases, Ninth Revision, code 354.0) and carpal tunnel injection (Current Procedural Terminology code 20526). The Rochester Epidemiology Project list of patients with diagnosis of carpal tunnel syndrome and a procedure of carpal tunnel injection within the specified time frame was retrieved using the computerized indexes, and the consolidated records of these patients were reviewed by three physicians (S.E., A.B., and T.S.) to verify the diagnosis. Information on the diagnosis was abstracted from the medical charts, and cases of possible or unlikely carpal tunnel syndrome (based on previously described criteria 18 ) were excluded from this study. In addition, detailed record abstraction was used to collect data on comorbidities, electrodiagnostic study severity, and volume and dose of injectate. Patients were followed through their medical record until 2014. The last day of followup was defined as the most recent day the patient had visited a Rochester Epidemiology Project health care provider, or December 31, 2014, if the patient visited a Rochester Epidemiology Project health care provider after 2014.
Patients were included if they had a diagnosis of primary carpal tunnel syndrome, had no previous injection for carpal tunnel syndrome or carpal tunnel release in that hand, received a therapeutic corticosteroid injection for carpal tunnel syndrome, were at least 18 years old, had at least 1 day of follow-up, and had provided research authorization. Patients diagnosed with pregnancy-related carpal tunnel syndrome and observations missing injectate volume or steroid dose were excluded from the analysis. Ultrasound-guided injections were excluded from analysis, because they were the subject of a different report and also because literature suggests that they have a different failure rate compared with blind injections. 19, 20 Study data were managed using Research Electronic Data Capture (REDCap).
The risk factors examined were age, sex, total injectate volume (combined steroid and anesthetic volume), effective dose of steroid, history of diabetes mellitus, diagnosis of peripheral neuropathy or cervical radiculopathy, diagnosis of rheumatoid arthritis, and electrodiagnostic study severity at the time of injection. Dose of steroid was standardized to equivalent effective dose of triamcinolone, which had the highest use in the cohort and was converted using Table 3 in Leversee. 21 The severity of carpal tunnel syndrome was assessed using available electrodiagnostic study Plastic and Reconstructive Surgery • August 2017 data. Electrodiagnostic study severity was classified in the following categories: normal, mild, moderate, and severe based on the classification of Stevens. 22 Subjects without information that allowed electrodiagnostic study severity to be assessed were assigned to a fifth electrodiagnostic study category: untested.
Outcome Measurements
Failure of treatment was the primary outcome of interest. Two definitions for failure of treatment were examined: (1) failure defined as any subsequent procedural intervention (i.e., corticosteroid injection or carpal tunnel release) and (2) failure defined as the patient receiving eventual carpal tunnel release on the injected hand regardless of the number of injections.
Statistical Analysis
Summary statistics for demographics and clinical characteristics are shown as number and percent, mean ± standard deviation, or median (interquartile range). Subjects without events were censored at the earlier of the date of last follow-up present in the medical record or December 31, 2014. The Kaplan-Meier method was used to estimate median failure time for both definitions of failure. Cox proportional hazard models with robust variance estimators were fit to test for covariates' associations with increased risk of treatment failure. Robust variance estimators were used to adjust for correlated outcomes between hands of the same patient. Model assumptions, such as proportional hazards, were assessed. Stratification was performed to adjust for variables failing the proportional hazard assumptions. Hazard ratios and 95 percent confidence intervals are reported. Values of p < 0.05 were considered significant. Statistical analyses were performed using R (version 3.1.2; Vienna, Austria); survival analyses used the survival package (version 2.39-4).
23-25
Comparison to Surgery without Previous Injection Cohort
To give an overview of the characteristics of the full cohort of patients treated for carpal tunnel syndrome, the group of patients who went directly to surgery was also examined. This allowed us to compare the patient-and disease-specific characteristics of the patients who received an injection to patients who proceeded directly to surgery within the specified time window and within the same population. Patients that proceeded directly to surgery were selected using the same resource as the injection cohort, with selection based on a Current Procedural Terminology code for diagnosis of carpal tunnel syndrome (International Classification of Diseases, Ninth Revision, code 354.0) and open carpal tunnel release (64721) or endoscopic carpal tunnel release (29848). The following were criteria for inclusion: diagnosis of primary carpal tunnel syndrome, no previous injection or surgery for carpal tunnel syndrome in that hand, no acute carpal tunnel syndrome, at least 18 years old, and provision of research authorization. Patients who received a therapeutic injection on either hand, including bilateral cases where only one hand was treated with injection, were excluded from this subset. Characteristics of interest were age, sex, electrodiagnostic study severity, history of diabetes mellitus, diagnosis of peripheral neuropathy or cervical radiculopathy, and diagnosis of rheumatoid arthritis. Under the assumption that distributions would be similar to the injection cohort, this group was randomly sampled to allow estimation of electrodiagnostic study severity proportions with a precision of ±5 percent. Chi-square or Wilcoxon rank sum tests were used to compare baseline characteristics between groups.
RESULTS
Patient Selection and Baseline Characteristics
A total of 1144 observations within the specified time window were identified. Of these, a total of 988 subjects had a primary diagnosis of carpal tunnel syndrome. Subjects who had pregnancyrelated carpal tunnel syndrome (n = 20), had ultrasound-guided procedures (n = 93), were missing injectate volume or dose of steroid (n = 88), and did not have at least 1 day of follow-up or had another indication for exclusion (n = 13) were also removed. After exclusions, there were a total of 774 affected hands in 595 distinct individuals (Fig. 1) .
Descriptive statistics are displayed in Table 1 , and whether they are reported at the subject or hand level is indicated. The cohort was 30.4 percent men, with 8.74 percent having a diagnosis of diabetes mellitus, 7.73 percent having peripheral neuropathy or cervical radiculopathy, and 5.38 percent having rheumatoid arthritis. The mean age at injection was 51 ± 13.5 years. The injections used an average injectate volume of 3.7 ± 1.16 ml and an average steroid dose of 39.9 ± 22.3 mg. For electrodiagnostic study severity, 14.5 percent were not tested, 8.3 percent were classified as normal, 29.6 percent were classified as mild, 41.2 percent were classified as moderate, and 6.5 percent were classified as severe. The median follow-up period was 7.3 years ( minimum, 7 days; maximum 12.6 years).
Overall, reintervention (injection or carpal tunnel release) was performed in 525 of 774 cases (67.8 percent), with eventual carpal tunnel release in 485 cases (62.7 percent). Median (interquartile range) time to failure was 259 days (121 to not applicable) for any retreatment and 446 days (147 to not applicable) for carpal tunnel release (Fig. 2) . Estimates of the 75th percentile for time to failure are not available, as that proportion of failure was not observed. There were 131 subjects (n = 159 hands) who received a second injection for treatment of carpal tunnel syndrome. Of these, 85 subjects [n = 100 hands (62.9 percent)] eventually were treated with carpal tunnel release.
Prognostic Factors
Results for Cox proportional hazard models are displayed in Tables 2 and 3 for the outcomes of any reintervention and carpal tunnel release, respectively. Electrodiagnostic study severity failed proportional hazard assumptions and was used as a stratifying variable. Figures 3 and 4 show the survival curves stratified by electrodiagnostic study severity. Although we are not able to formally test within the context of the model between strata, these curves indicate that patients with more severe electrodiagnostic study results were more likely to experience injection failure. Higher injectate volume was found to be significantly associated with a decreased likelihood of injection failure for the outcome of any retreatment [hazard ratio, 0. Plastic and Reconstructive Surgery • August 2017 
Injection versus Surgical Cohort
There were 931 unique subjects who underwent carpal tunnel surgery without previously receiving an injection in 2001 to 2010; 300 were randomly selected to represent this group. Of the 300 subjects in the direct-to-surgery sample, 104 had surgery on both hands (total, n = 404 hands), 35.3 percent were male, 15.7 percent had diabetes mellitus, 2.0 percent had rheumatoid arthritis, and 8.33 percent had peripheral neuropathy or cervical radiculopathy. They were on average 55.0 ± 14 years of age, and 9.65, 3.47, 16.3, 44.8, and 25.7 percent had electrodiagnostic study severities of untested, normal, mild, moderate, and severe, respectively. Compared with the injection cohort, these patients were older (p < 0.001) and had a lower incidence of rheumatoid arthritis (p = 0.028), a higher incidence of diabetes (p = 0.003), and more severe electrodiagnostic study results (p < 0.001). Table 4 shows the demographics and clinical characteristics of the surgical sample and comparison to characteristics of the injection cohort.
DISCUSSION
In this population-based cohort with a median follow-up of 7.4 years, 32 percent of the subjects did not receive subsequent treatment after a single steroid injection. The presence of rheumatoid arthritis and a higher volume of injectate were associated with decreased likelihood of subsequent treatment.
Most guidelines suggest a course of nonoperative treatment in patients diagnosed with carpal tunnel syndrome; however, there remains controversy about the role of steroid injections. Some physicians consider corticosteroid injections to be a diagnostic tool only. 4, 5 It has been suggested that regional variation in the use of surgery for many conditions is mainly a result of physician beliefs about the indications for surgery. 18, 26 This may explain the regional variation in rates of carpal tunnel release. 27 Our result, that approximately one-third of patients did not receive subsequent Plastic and Reconstructive Surgery • August 2017 treatment in the long term, suggests a role for corticosteroid injections in the treatment of carpal tunnel syndrome. A local corticosteroid injection is less invasive and less expensive compared with surgery and does not require time off from work. Although corticosteroid injections do come with risks and potential adverse events, as median nerve injury or infection may occur, 28 the low morbidity and low cost of a steroid injection make it an excellent form of initial treatment in some carpal tunnel syndrome patients. [29] [30] [31] We believe that this approach is especially relevant because the natural history of carpal tunnel syndrome remains unknown, and some patients experience spontaneous improvement in their symptoms, with reported rates of 33 to 40 percent experiencing some improvement, depending on electrodiagnostic study severity. [32] [33] [34] [35] The rate of subsequent treatment found in this study correlates with previous studies, which mostly looked at shorter term follow-up. Meys et al. followed 113 patients who received an injection for carpal tunnel syndrome and found that 67 percent had surgery within 1 year. 12 Jenkins et al. found that 33 percent of the patients receiving a local corticosteroid injection underwent carpal tunnel release within 5 years after initial treatment. 13 The proportion is lower than in our study, but their result was based on patients with mild to moderately severe carpal tunnel syndrome only. Berger et al. found that 75 percent underwent surgery after a single injection, a slightly higher proportion than our result. 10 In that prospective study, patients were offered a reinjection or surgery when there was minor or no relief of symptoms at follow-up, which might have resulted in a higher proportion of injection failure. A randomized placebo-controlled trial on the effect of steroid dose showed a surgery rate of 73 to 81 percent at 1-year follow-up. 8 The choice to proceed to surgery was made solely by the patient; however, the study design might make it challenging to extrapolate the failure rate to a clinical setting, because the participation in a randomized controlled trial and chance of receiving a placebo injection may heighten vigilance of patients, thereby increasing the chance of residual symptoms. 36 Our retrospective study was free from this type of bias.
The proportion of patients undergoing surgery after the second injection was similar to the proportion proceeding to surgery after one injection. Ashworth and Bland assessed the effectiveness of second corticosteroid injections for carpal tunnel syndrome in 229 patients. 37 They found that the change in Boston Symptom Severity Scale and Functional Status Scale was not significantly different between first and second injections and concluded that second injections appear to be at least as effective as first injections. To the best of our knowledge, the maximum number of injections that an individual might benefit from is unknown. 10 Several risk factors for recurrence after a single steroid injection have previously been identified. However, the negative association between a diagnosis of rheumatoid arthritis and subsequent treatment found in this study has not been previously described. Rheumatoid arthritis-associated carpal tunnel syndrome might respond better to an injection because of the underlying pathophysiology: an inflammatory condition versus noninflammatory fibrosis in idiopathic carpal tunnel syndrome. 38 However, we cannot rule out that rheumatoid arthritis was a confounder in our cohort. Rheumatologists might be less likely to refer patients to a hand surgeon for a carpal tunnel release. The effect of volume of injection has not been studied in depth. A Cochrane review by Marshall et al. stated that no particular dosage or type of medication provided a superior outcome for the treatment of carpal tunnel syndrome. 6 Our results that a larger volume of injection is associated with a lower risk of injection failure could be related to greater fluid distribution or greater contact area with the soft tissues within the carpal tunnel. 39 The finding that patients with more severe electrodiagnostic study results are more likely to experience injection failure has already been documented. 14 In contrast to previous studies, we did not find a diagnosis of diabetes mellitus to be a predictor for subsequent treatment. 11, 13, 15 However, there was a significantly smaller proportion of patients with diabetes mellitus in the injection cohort compared with the surgical sample. Thus, patients with diabetes mellitus might have had more severe carpal tunnel syndrome and were therefore more likely to proceed to surgery directly or their physicians may have been more likely to operate on carpal tunnel syndrome patients with diabetes because it has already been well-described that they are less likely to benefit from an injection.
Our study has some limitations. First, this study was retrospective in design and lacked a control group. Ideally, there should have been a control group of patients without treatment, because some patients improve spontaneously. 34, 35 Second, our outcome measure where failure of injection is defined as receiving subsequent treatment may not adequately capture clinically relevant failures, where patients have ongoing symptoms of carpal tunnel syndrome but elect for some other reason not to receive subsequent treatment. Third, there was variability in techniques of corticosteroid injection that were used. Literature suggests that some techniques are more effective than others and this might have affected the results. 39, 40 Fourth, although the study is based on a large number of patients, we have to take into account an exclusion of approximately 7 percent of potential cases because the patients had not authorized the use of their medical records for research. 16 Finally, despite the comprehensive nature of the Rochester Epidemiology Project medical record linkage system, it is possible that some patients received treatment from non-Rochester Epidemiology
